Uveitis

Researchers at the Eye Clinic of the University Hospital Bonn (UKB) and the University of Bonn have tested a new imaging method for monitoring intermediate uveitis.

The licensing deal includes upfront, development milestones, and sales royalties, with additional considerations throughout the term of the agreement.

TRS01 ophthalmic solution is targeted for the treatment of non-infectious uveitis, including uveitic glaucoma.

This partnership will provide Greater Tampa Bay community with services for the treatment of uveitis and retina care.

The study will evaluate the safety and efficacy of fluocinolone acetonide intravitreal implant 0.18mg, (YUTIQ) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.

This retrospective, cross-sectional study identified all inpatient diagnosed with syphilitic uveitis in the US between 2010 and 2019.

TRS01 has the potential to be the first-line treatment option for non-infectious uveitis, according to the company.

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

Launched in 2014, Intelligent Research in Sight is the nation's first and largest comprehensive eye disease registry.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The week of September 18-24 will be dedicated to educating the public on IEDs such as uveitis, keratitis, conjunctivitis and more.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.

This allosteric tyrosine kinase (TYK2) inhibitor may help to treat the disregulation of TYK2 mediated pathways may also play an important role in conditions, including noninfectious uveitis.

The severity and duration of gene therapy–associated uveitis correlated with increasing vector dose.

As a nonsteroid treatment, RG6179 could open new methods for controlling inflammation with fewer adverse effects.

The sale of YUTIQ® will empower EyePoint Pharmaceuticals to continue to advance its pipeline of therapeutics through the company's upcoming clinical trials.

New clinic dedicated to treating pediatric uveitis opens in the UAE.

Research highlights the correlation between the gut microbiome and autoimmune disorders.

An end-of-week review of retina news and stories from October 29-November 3, 2022.